Back to Authors

Guarda, Max

https://orcid.org/0009-0005-9163-0781

Mayo Clinic

Mayo Clinic

Citations 5

Abstract 4146301: Relationship Between Calf Muscle Pump Function and Exercise Stress Testing
Liedl, David , Bonikowske, Amanda R. , Guarda, Max , Ghorbanzadeh, Atefeh , McBane, Robert D. , Houghton, Damon E.

Circulation | November 11, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4146301 Get It

Background: Exercise stress testing uses metabolic equivalents of tasks (METs) to measure the energy cost of activities, aiding in the assessment of exercise capacity and cardiovascular health. Despite its significance, the correlation between calf muscle pump function (CPF) and exercise stress testing remains unexplored. We aimed to evaluate the relationship between CPF and peak METs as determined by cardiopulmonary treadmill exercise stress testing. Methods: The study included adults who underwent exercise cardiopulmonary stress testing and venous plethysmography at Mayo Clinic between April 2017 and March 2020. The protocols other than Bruce, Mayo, Modified Naughton, and Naughton protocols were excluded. The CPF ejection fraction (EF) was calculated per leg based on refill volumes post-exercise as a percentage of passive drain refill. The classification of CEAP (Clinical-Etiology-Anatomy-Pathophysiology) was utilized to better understand chronic venous insufficiency (CVI). Results: A total of 155 patients who underwent both exercise stress testing and venous plethysmography were included, with a mean age of 61.31 ± 14.03 years, and 84 (54.2%) were male. The peak measured METs for normal, unilaterally reduced, and bilaterally reduced CPF were 8.5 (2.5), 7.3 (2.1), and 7.1 (2.4), respectively (p=0.004, Figure 1). Multiple linear regression models were developed with METs as the outcome to determine if CPF was an independent predictor of METs on cardiopulmonary exercise stress testing. IIn model 1, the following independent variables were included: resting heart rate, peak heart rate, peak systolic blood pressure, recovery heart rate at minute 1, and worst EF (Table 1). In model 1, with only exercise parameters, lower EF was associated with lower METs (p=0.03). In a second analysis, variables identified as statistically significant with METs in the initial model were included, along with CEAP class (model 2) and CCI (model 3) (Table 2). In model 2, CEAP class 3 or higher was associated with decreased METs on the exercise stress test. This correlation implies that individuals with moderate to severe CVI may influence exercise capacity, demonstrating the interconnectedness of the cardiovascular system. Moreover, in model 3, the CCI, a predictor for mortality, was not significantly associated with METs. Conclusion: Our findings revealed that more severe CVI (CEAP class and reduced CPF) was associated with reduced exercise capacity after accounting for other factors.
Giant cell arteritis in patients with systemic sclerosis: a case series
Guarda, Max , Roy, Alexandria , Burke, Michelle, Warrington, Kenneth J. , Koster, Matthew J.

Clinical and Experimental Rheumatology | March 21, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/pn1o3u Get It

Rheumatic masqueraders: mimics of primary vasculitis - a case-based review
Koster, Matthew J. , Guarda, Max , Ghaffar, Umar , Warrington, Kenneth J. , Warrington, Kenneth J , Koster, Matthew J

Expert Review of Clinical Immunology | October 14, 2023 | Volume: 20 | Issue: 1 | Pages: 83-95

10.1080/1744666x.2023.2270774 Get It

Clinical Images: Tongue ulceration in giant cell arteritis associated with asymptomatic retinal ischemia
Guarda, Max , Ghaffar, Umar , Koster, Matthew J. , Koster, Matthew J , Warrington, Kenneth J.

ACR Open Rheumatology | April 8, 2023 | Volume: 5 | Issue: 7 | Pages: 331-331

10.1002/acr2.11544 Get It

New-onset aortitis manifesting as relapsing giant cell arteritis successfully managed with tocilizumab monotherapy. A comment on: Optimisation of tocilizumab therapy in giant cell arteritis. by Calderon-Goercke et al.
Guarda, Max , Araoz, Philip A. , Ghaffar, Umar , Warrington, Kenneth J. , Koster, Matthew J.

Clinical and Experimental Rheumatology | March 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/032qke Get It